Key Takeaways
- • CLO equity is the junior-most tranche of a collateralized loan obligation and receives residual cash flows from the loan portfolio after interest is paid to debt investors, according to publisher material from Nuveen.
- • The equity tranche generally represents about 10% of a CLO's capital structure, with underwriters typically providing leverage on the amount equity investors post.
- • Nuveen argues that CLO equity may be worth considering for investors who can tolerate some illiquidity, as it can help asset owners diversify away from valuation risks in private equity allocations.
- • CLOs hold diversified portfolios of broadly syndicated, liquid, senior secured corporate loans with an average facility size of roughly $1.1bn, per the publisher's materials.
- • CLO equity is typically issued and traded in markets with limited or no price disclosure, which makes investment performance difficult to gauge.
Summary
A Nuveen article published through the IPE Reference Hub examines where CLO equity fits within institutional investor allocations, framing the asset class as a potential complement to private equity holdings. According to the publisher's materials, CLO equity has attracted growing investor interest, largely because of its potential for high returns driven by a robust yield profile and current income.
Structurally, CLO equity is the junior-most tranche of a collateralized loan obligation. It absorbs the residual cash flows from the underlying loan portfolio after interest payments are made to debt investors. The equity generally represents about 10% of the capital structure, and underwriters typically provide leverage against the amount equity investors post. The result, as the materials describe it, is leveraged exposure to first lien senior secured loans, with the CLO's securitization structure dividing cash flows across tranches.
The underlying collateral consists of diversified portfolios of broadly syndicated, liquid, senior secured corporate loans. Nuveen's materials cite an average facility size of roughly $1.1bn for these loans. The publisher positions CLO equity as occupying a distinctly different place on the risk-return spectrum than conventional debt tranches, representing a leveraged residual exposure to the loan pool.
Nuveen contends that for investors able to accept some illiquidity, CLO equity can help mitigate concentration in private equity valuations by diversifying exposure away from the valuation risks inherent in those allocations. The firm presents this as a rationale for considering the asset class alongside private equity alternatives.
Investors should note the limitations flagged in the broader literature. CLO equity is usually issued and traded in markets with limited or no price disclosure, which complicates performance measurement and due diligence.
Structurally, CLO equity is the junior-most tranche of a collateralized loan obligation. It absorbs the residual cash flows from the underlying loan portfolio after interest payments are made to debt investors. The equity generally represents about 10% of the capital structure, and underwriters typically provide leverage against the amount equity investors post. The result, as the materials describe it, is leveraged exposure to first lien senior secured loans, with the CLO's securitization structure dividing cash flows across tranches.
The underlying collateral consists of diversified portfolios of broadly syndicated, liquid, senior secured corporate loans. Nuveen's materials cite an average facility size of roughly $1.1bn for these loans. The publisher positions CLO equity as occupying a distinctly different place on the risk-return spectrum than conventional debt tranches, representing a leveraged residual exposure to the loan pool.
Nuveen contends that for investors able to accept some illiquidity, CLO equity can help mitigate concentration in private equity valuations by diversifying exposure away from the valuation risks inherent in those allocations. The firm presents this as a rationale for considering the asset class alongside private equity alternatives.
Investors should note the limitations flagged in the broader literature. CLO equity is usually issued and traded in markets with limited or no price disclosure, which complicates performance measurement and due diligence.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.